Literature DB >> 18618249

Validation of prognostic indices using the frailty model.

C Legrand1, L Duchateau, P Janssen, V Ducrocq, R Sylvester.   

Abstract

A major issue when proposing a new prognostic index is its generalisibility to daily clinical practice. Validation is therefore required. Most validation techniques assess whether "on average" the results obtained by the prognostic index in classifying patients in a new sample of patients are similar to the results obtained in the construction set. We introduce a new important aspect of the generalisibility of a prognostic index: the heterogeneity of the prognostic index risk group hazard ratios over different centers. If substantial variability between centers exists, the prognostic index may have no discriminatory capability in some of the centers. To model such heterogeneity, we use a frailty model including a random center effect and a random prognostic index by center interaction. Statistical inference is based on a Bayesian approach using a Laplacian approximation for the marginal posterior distribution of the variances of the random effects. We investigate different ways to summarize the information available from this marginal posterior distribution. Our approach is applied to a real bladder cancer database for which we demonstrate how to investigate and interpret heterogeneity in prognostic index effect over centers.

Entities:  

Mesh:

Year:  2008        PMID: 18618249     DOI: 10.1007/s10985-008-9092-2

Source DB:  PubMed          Journal:  Lifetime Data Anal        ISSN: 1380-7870            Impact factor:   1.588


  30 in total

1.  Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials.

Authors:  T Yamaguchi; Y Ohashi; Y Matsuyama
Journal:  Stat Methods Med Res       Date:  2002-06       Impact factor: 3.021

2.  Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer.

Authors:  Patrick Royston; Mahesh K B Parmar; Richard Sylvester
Journal:  Stat Med       Date:  2004-03-30       Impact factor: 2.373

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Explained variation in survival analysis.

Authors:  M Schemper; J Stare
Journal:  Stat Med       Date:  1996-10-15       Impact factor: 2.373

5.  4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index.

Authors:  François Blanchon; Michel Grivaux; Bernard Asselain; François-Xavier Lebas; Jean-Pierre Orlando; Jacques Piquet; Mahmoud Zureik
Journal:  Lancet Oncol       Date:  2006-10       Impact factor: 41.316

6.  Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group.

Authors:  C Bouffioux; K H Kurth; A Bono; W Oosterlinck; C B Kruger; M De Pauw; R Sylvester
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

7.  Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes.

Authors:  Catrin Tudur Smith; Paula R Williamson; Anthony G Marson
Journal:  Stat Med       Date:  2005-05-15       Impact factor: 2.373

8.  Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European organization for research on treatment of cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone.

Authors:  K H Kurth; F H Schröder; U Tunn; R Ay; M Pavone-Macaluso; F Debruyne; M de Pauw; O Dalesio; F ten Kate
Journal:  J Urol       Date:  1984-08       Impact factor: 7.450

9.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

10.  Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.

Authors:  D W Newling; M R Robinson; P H Smith; D Byar; R Lockwood; I Stevens; M De Pauw; R Sylvester
Journal:  Eur Urol       Date:  1995       Impact factor: 20.096

View more
  1 in total

1.  Prediction models need appropriate internal, internal-external, and external validation.

Authors:  Ewout W Steyerberg; Frank E Harrell
Journal:  J Clin Epidemiol       Date:  2015-04-18       Impact factor: 6.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.